IDEXX Cancer Dx testing

Medical evidence

Dedicated to scientific rigor.

IDEXX Cancer Dx testing is extensively validated for accuracy across diverse clinical conditions. With 79% sensitivity and 99% specificity,¹ the test offers diagnostic accuracy that is comparable to, if not superior to, human oncology screening standards.² Ongoing medical studies underscore our dedication to transparency and scientific rigor, and they have already resulted in new findings and use cases for IDEXX Cancer Dx testing. And this is just the beginning.

White paper

Our white paper gives you access to validation data about IDEXX Cancer Dx testing, including findings in dogs with confirmed lymphoma, healthy dogs, and those with other active diseases.

Download white paper

“IDEXX Cancer Dx is a powerful innovation in oncology diagnostics that enables veterinarians the opportunity to intervene sooner, improving the quality of life for canine cancer patients.”

Tim Fan, DVM, PhD, DACVIM
(Oncology, Small Animal Internal Medicine)

Medical studies

IDEXX has multiple studies in progress and in anticipation of publication in peer-reviewed journals. Access the following videos for overviews of data shared at the 2025 Veterinary Cancer Society Annual Conference.
.

Early Detection of Lymphoma by IDEXX Cancer Dx Testing in 7 Cases

IDEXX Cancer Dx testing was retrospectively performed on over 11,000 whole blood and serum samples, revealing biomarker changes in a total of 88 cases. Of these, 17 dogs showed biomarker detection during routine wellness visits, and 7 of these 17 dogs were later diagnosed with lymphoma, highlighting its potential for early detection, in support of our ongoing prospective longitudinal study.

Download study

Pilot Evaluation of IDEXX Cancer Dx Testing for Monitoring CHOP Treatment Response in Canine Lymphoma

Ten treatment-naïve dogs with confirmed lymphoma were prospectively enrolled to assess the utility of IDEXX Cancer Dx testing as a monitoring tool during a 25-week CHOP protocol. IDEXX Cancer Dx results correlated with clinical remission, indicating this liquid biopsy test may aid remission monitoring and warrants validation in larger cohorts.